Get to know our clinical trials
Clinical trial of MCLA-129 in patients with advanced NSCLC and other solid tumors
THE AIM OF THIS STUDY IS TO FIND OUT THE POSSIBLE SIDE EFFECTS OF THE STUDY DRUG, WHETHER THE STUDY DRUG CAN STOP THE GROWTH OR SPREAD OF CANCER CELLS IN YOUR BODY, HOW YOUR BODY PROCESSES THE STUDY DRUG, AND HOW CERTAIN BIOMARKERS OR SMALL SUBSTANCES IN YOUR BODY CHANGE IN RESPONSE TO THE STUDY DRUG.
Technical Summary
- PHASE I/II DOSE ESCALATION AND DOSE-ESCALATION STUDY TO EVALUATE MCLA-129, A HUMAN ANTI-EGFR AND ANTI-C-MET BISPECIFIC ANTIBODY, IN PATIENTS WITH ADVANCED NSCLC AND OTHER SOLID TUMORS
- Code EudraCT: .
- Protocol number: MCLA-129-CL01
- Promoter: Merus N.V.
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.